Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.

Alumis Inc. Common Stock

A company that transforms the lives of patients living with immune-mediated diseases using a precision approach to develop oral therapies.

Alumis

At Alumis, our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.

We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. 

Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, and right endpoint resulting in optimized outcomes for patients. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. 

Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.

Today we announced the pricing of our initial public offering: https://bit.ly/3zwhdvh #NasdaqListed

Today, we honor #Juneteenth, celebrating freedom, resilience, and progress. As we reflect on this important day in history, we’re committed to fostering diversity and inclusion at Alumis. #FreedomDay

Alumis’ clinical development team attended the EULAR - European Alliance of Associations for Rheumatology 2024 Congress earlier this month in Vienna! With the goal of driving progress in the clinical care of people with rheumatic diseases, the annual meeting brings together patients, health professionals, rheumatologists and industry partners to showcase the latest scientific breakthroughs in clinical, translational, and basic research. We were thrilled to be part of this meeting as we advance our #lupus clinical trial LUMUS! #EULAR2024

This #PrideMonth, we celebrate the vibrant LGBTQIA+ community and recognize their invaluable contributions to science and biotechnology. Together, we stand proud in our commitment to diversity, inclusion, and equality. #Pride2024

Did you know that women are disproportionately affected by #lupus? To learn more about lupus this #LupusAwarenessMonth, check out resources and information from @LupusResearch: https://lnkd.in/esmUVvvw

We are thrilled to announce our initial public offering, trading on Nasdaq under the ticker $ALMS! This achievement wouldn't have been possible without the relentless dedication of our incredible team, as well as the support of our Board of Directors and investors. Thank you to everyone who helped us reach this critical milestone in support of our mission to improve the lives of patients with immune-mediated diseases. #NasdaqListed

	Dec '22	Dec '23
average inventory
average payables		1.42M -
average receivables		557K -
book value per share	12.03 -	0.70 94.21%
capex per share	0.32 -	0.09 72.96%
capex to depreciation	9.62 -	3.50 63.59%
capex to operating cash flow	-0.02 -	-0.03 54.98%
capex to revenue
cash per share	12.41 -	0.94 92.39%
days of inventory on hand
days payables outstanding	2.51K -	317.81 87.34%
days sales outstanding
debt to assets
debt to equity
dividend yield
earnings yield	-1.12 -	-0.22 79.97%
enterprise value	75.68M -	676.12M 793.38%
enterprise value over ebitda	-0.67 -	-4.31 546.87%
ev to operating cash flow	-0.70 -	-5.20 640.42%
ev to sales
free cash flow per share	-14.69 -	-2.59 82.34%
free cash flow yield	-1.10 -	-0.20 82.34%
graham net net	10.07 -	-0.08 100.78%
graham number	63.58 -	6.84 89.23%
income quality	0.96 -	0.84 12.87%
intangibles to total assets	0 -	0
interest coverage
interest debt per share
inventory turnover
invested capital	93.68M -	67.71M 27.72%
market cap	99.72M -	689.53M 591.48%
net current asset value	84.62M -	-145K 100.17%
net debt to ebitda	0.21 -	0.09 59.59%
net income per share	-14.93 -	-2.99 79.97%
operating cash flow per share	-14.37 -	-2.51 82.55%
payables turnover	0.15 -	1.15 690.15%
receivables turnover
research and ddevelopement to revenue
return on tangible assets	-1.03 -	-1.73 67.15%
revenue per share
roe	-1.24 -	-4.29 246.01%
roic	-1.26 -	-4.38 247.16%
sales general and administrative to revenue
shareholders equity per share	12.03 -	0.70 94.21%
stock based compensation to revenue
tangible asset value	90.23M -	36.11M 59.98%
tangible book value per share	12.03 -	0.70 94.21%
working capital	89.20M -	32.49M 63.58%

ALMS

COM:ALUMIS

Alumis

Last Close

9.44

22/11 21:00

Market Cap

668.34M

Beta: -

Volume Today

115.52K

Avg: -

Preview